Rivaroxaban or Combo Therapy: A Winner for All Ages? – Medscape
Rivaroxaban or Combo Therapy: A Winner for All Ages? Medscape Rivaroxaban Monotherapy Benefits Those with Atrial Fibrillation, Stable Coronary…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
FDA Approves First Treatment for MAS in Still Disease
The FDA has approved the interferon gamma-blocking antibody emapalumab-lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS)…
More Days, More Resistance: Time to Rethink Antibiotics
“One of the most universally accepted beliefs around the world,” said Brad Spellberg, MD, chief medical officer at…